血液スクリーニング市場：技術別（核酸増幅法、（リアルタイムPCR）、ELISA（化学発光免疫測定法）、ラピッドテスト、ウェスタンブロット）、製品別（装置、試薬・キット、ソフトウェア）、エンドユーザー別（血液銀行、病院） - 2026年までの世界予測

Blood Screening Market by Technology (Nucleic Acid Amplification, (Real-Time PCR), ELISA (Chemiluminescence immunoassay), Rapid Test, Western Blot), Product (Instrument, Reagent & Kits, Software) & End User (Blood Bank, Hospital) - Global Forecast to 2026

世界の血液スクリーニング市場は、2021年の25億米ドルから2026年には38億米ドルに達すると予測されており、予測期間中のCAGRは8.4%となっています。この市場の成長は主に、世界中での献血数の増加、感染症の蔓延... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2021年12月1日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	237	256	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界の血液スクリーニング市場は、2021年の25億米ドルから2026年には38億米ドルに達すると予測されており、予測期間中のCAGRは8.4%となっています。この市場の成長は主に、世界中での献血数の増加、感染症の蔓延、献血された血液の需要の高まりによってもたらされています。

"血液スクリーニング市場の製品・サービス別では、予測期間中、試薬・キット分野が最も高い成長率を示しました。"
血液スクリーニング市場は、製品別に試薬＆キット、機器、ソフトウェア＆サービスに分かれています。2020年の血液スクリーニング市場では、試薬・キット分野が最も高い成長率を示しました。市場の成長は、輸血や献血の件数が増加していることに大きく起因しています。さらに、血液スクリーニング技術の技術的進歩と手術件数の増加が、このセグメントの成長を刺激しています。
"血液銀行セグメントが最も高いCAGRを占めています。"
エンドユーザーに基づいて、血液スクリーニング市場は、血液銀行と病院に分けられます。2020年には、血液銀行セグメントが最も高い成長率を占めました。これは、臓器移植手術の増加や、血液の安全性に対する意識の高まりに起因すると考えられます。
"アジア太平洋地域。最も急成長している地域の血液スクリーニング市場"
世界の血液スクリーニング市場は、北米、欧州、アジア太平洋地域、ラテンアメリカ、中東・アフリカに分かれています。予測期間中、アジア太平洋地域が最も高いCAGRを記録すると予測されています。アジア太平洋地域では、医療費の増加、病気の早期発見に対する政府の取り組みの増加、一人当たりの所得の増加、APAC各国での民間病院の農村部への拡大、APAC各国での高齢者人口の増加（慢性疾患の増加と相まって）、高成長市場の存在などの要因が挙げられています。また、人件費が安く、規制環境が整っていることも、この地域の市場成長を促進すると考えられます。

本レポートのために行われた主要なインタビューは、以下のように分類されます。

- 企業タイプ別。企業タイプ別：ティア1-40%、ティア2-30%、ティア3-30
- 呼称別Cレベル：27％、Dレベル：18％、その他：55
- 地域別地域別：北米51％、欧州21％、アジア太平洋地域18％、ラテンアメリカ6％、中東・アフリカ4
レポートに掲載されている企業の一覧です。

- Grifols社（スペイン）
- F. ホフマン・ラ・ロシュ社（スイス(スイス)
- アボット・ラボラトリーズ・インク（米国(米国）、bioMérieux（フランス）
- Bio-Rad Laboratories, Inc.(米国)
- ベクトン・ディッキンソン・アンド・カンパニー（米国）
- ベックマン・コールター社（Beckman Coulter, Inc.(ダナハー）（米国）
- DiaSorin（イタリア）
- シーメンス・ヘルシネアーズ（ドイツ）
- サーモフィッシャーサイエンティフィック社（米国(米国)
- Ortho Clinical Diagnostics Inc.(米国)
- GEヘルスケア(米国)
- Merck KGaA（ドイツ）
- パーキンエルマー（米国）
- Bio-Techne Corporation (米国)
- GFE（ドイツ）
- Trinity Biotech（アイルランド）
- Mindray（中国）
- Maccura Biotechnology Co., Ltd. (中国)(中国)
- Immucor, Inc.(米国)
- Cellabs（オーストラリア）
- アブノバ・コーポレーション（台湾）
- Enzo Biochem, Inc.(米国)
- Cepheid（米国）。
調査対象。
本レポートでは、世界の血液スクリーニング市場の詳細を明らかにしています。製品・サービス、技術、エンドユーザー、地域など、さまざまなセグメントにおける市場規模と今後の成長性を推定することを目的としています。また、主要な市場参加者の会社概要、最近の開発状況、主要な市場戦略など、綿密な競合分析を行っています。

このレポートを購入する主なメリット
本レポートは、血液スクリーニング市場全体とそのサブセグメントの収益数値の最も近い近似値を提供することで、市場リーダー/新規参入者を支援します。また、ステークホルダーが競合状況をより深く理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるための知見を得るのにも役立ちます。本レポートは、ステークホルダーが市場の脈動を理解し、主要な市場の推進要因、抑制要因、機会、課題に関する情報を提供することを可能にします。

ページTOPに戻る

1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 22
1.2.2 MARKETS COVERED 23
FIGURE 1 BLOOD SCREENING MARKET SEGMENTATION 23
1.2.3 YEARS CONSIDERED FOR THE STUDY 24
1.3 CURRENCY 24
1.4 LIMITATIONS 24
1.5 STAKEHOLDERS 25
1.6 SUMMARY OF CHANGES 25
2 RESEARCH METHODOLOGY 27
2.1 RESEARCH DATA 27
2.2 RESEARCH APPROACH 27
FIGURE 2 BLOOD SCREENING MARKET: RESEARCH DESIGN 27
2.2.1 SECONDARY DATA 28
2.2.1.1 Key data from secondary sources 28
2.2.2 PRIMARY DATA 29
2.2.2.1 Primary sources 30
2.2.2.2 Key data from primary sources 31
2.2.2.3 Key industry insights 32
2.2.2.4 Breakdown of primary interviews 32
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (BLOOD SCREENING MARKET) 32
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 33
2.3 MARKET SIZE ESTIMATION 33
2.3.1 BOTTOM-UP APPROACH 34
2.3.1.1 Approach 1: Company revenue estimation approach 34
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 34
2.3.1.2 Approach 2: Presentations of companies and primary interviews 34
2.3.1.3 Growth forecast 35
2.3.1.4 CAGR projections 35
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 35
2.3.2 TOP-DOWN APPROACH 35
FIGURE 7 BLOOD SCREENING MARKET: TOP-DOWN APPROACH 36
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 37
FIGURE 8 DATA TRIANGULATION METHODOLOGY 37
2.5 MARKET SHARE 38
2.6 ASSUMPTIONS FOR THE STUDY 38
2.7 LIMITATIONS 39
2.8 RISK ASSESSMENT 39
2.8.1 RISK ASSESSMENT: BLOOD SCREENING MARKET 39
2.9 GROWTH RATE ASSUMPTIONS 40
2.10 COVID-19 HEALTH ASSESSMENT 40
2.11 COVID-19 ECONOMIC ASSESSMENT 40
2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 41
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY 41
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 42
2.13 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE BLOOD SCREENING MARKET 43
3 EXECUTIVE SUMMARY 44
FIGURE 11 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE,
2021 VS. 2026 (USD MILLION) 44
FIGURE 12 BLOOD SCREENING MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD MILLION) 45
FIGURE 13 BLOOD SCREENING MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 45
FIGURE 14 BLOOD SCREENING MARKET, BY REGION, 2021 VS. 2026 (USD MILLION) 46
4 PREMIUM INSIGHTS 47
4.1 BLOOD SCREENING MARKET OVERVIEW 47
FIGURE 15 GROWING NUMBER OF BLOOD DONATIONS AND INCREASING PREVALENCE OF INFECTIOUS DISEASES DRIVE MARKET GROWTH 47
4.2 BLOOD SCREENING MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026 48
FIGURE 16 REAGENTS & KITS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026 48
4.3 BLOOD SCREENING MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026 48
FIGURE 17 NUCLEIC ACID TEST SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 48
4.4 BLOOD SCREENING MARKET SHARE, BY END USER, 2021 VS. 2026 49
FIGURE 18 BLOOD BANKS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026 49
4.5 BLOOD SCREENING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49
FIGURE 19 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE BLOOD SCREENING MARKET DURING THE FORECAST PERIOD 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
FIGURE 20 BLOOD SCREENING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50

5.2.1 DRIVERS 51
5.2.1.1 Rising number of blood donations 51
TABLE 1 GLOBAL CANCER PREVALENCE, 2018 VS. 2025 51
5.2.1.2 Rising prevalence of infectious diseases and emergence of newer pathogens 52
5.2.2 RESTRAINTS 52
5.2.2.1 Alternative technologies 52
5.2.3 OPPORTUNITIES 53
5.2.3.1 Technological advancements 53
5.2.3.2 Emerging economies offer lucrative opportunities 53
5.2.4 CHALLENGES 54
5.2.4.1 High cost of blood screening technologies 54
5.2.4.2 Usage of low-sensitivity screening 54
5.3 IMPACT OF COVID-19 ON THE BLOOD SCREENING MARKET 55
5.4 PESSIMISTIC, OPTIMISTIC, AND REALISTIC SCENARIOS 56
5.4.1 BLOOD SCREENING MARKET 56
FIGURE 21 PESSIMISTIC SCENARIO 56
FIGURE 22 OPTIMISTIC SCENARIO 56
FIGURE 23 REALISTIC SCENARIO 57
5.5 PRICING ANALYSIS 57
TABLE 2 PRICE OF BLOOD SCREENING PRODUCTS (2021) 57
5.6 PATENT ANALYSIS 58
5.6.1 PATENT ANALYSIS OF NAT 58
5.6.2 PATENT ANALYSIS OF ELISA 58
5.7 TRADE ANALYSIS 59
5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC REAGENTS 59
TABLE 3 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION) 59
TABLE 4 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION) 59
5.8 VALUE CHAIN ANALYSIS 60
FIGURE 24 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE 60
5.9 SUPPLY CHAIN ANALYSIS 61
FIGURE 25 BLOOD SCREENING MARKET: SUPPLY CHAIN ANALYSIS 61
5.10 ECOSYSTEM ANALYSIS OF THE BLOOD SCREENING MARKET 62
FIGURE 26 BLOOD SCREENING MARKET: ECOSYSTEM ANALYSIS 62
5.10.1 ROLE IN ECOSYSTEM 62
5.11 PORTER’S FIVE FORCES ANALYSIS 63
TABLE 5 BLOOD SCREENING MARKET: PORTER’S FIVE FORCES ANALYSIS 63
5.11.1 THREAT OF NEW ENTRANTS 63
5.11.2 THREAT OF SUBSTITUTES 63
5.11.3 BARGAINING POWER OF BUYERS 63
5.11.4 BARGAINING POWER OF SUPPLIERS 63
5.11.5 DEGREE OF COMPETITION 64
5.12 REGULATORY LANDSCAPE 64
5.12.1 NORTH AMERICA 64
5.12.1.1 US 64
5.12.1.2 CANADA 64
5.12.2 EUROPE 64
5.12.3 ASIA PACIFIC 65
5.12.3.1 JAPAN 65
5.12.3.2 INDIA 65
5.12.4 LATIN AMERICA 65
5.12.4.1 BRAZIL 65
5.12.5 MIDDLE EAST 66
5.13 CASE STUDY ANALYSIS 66
5.13.1 CASE STUDY 1 66
5.13.2 CASE STUDY 2 67
5.14 TECHNOLOGY ANALYSIS 67
5.15 TRENDS/DISRUPTIONS IMPACTING THE BUSINESS OF CUSTOMERS 68
5.15.1 REVENUE SOURCES ARE SHIFTING TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO THE COVID-19 PANDEMIC 68
FIGURE 27 REVENUE SHIFT FOR THE BLOOD SCREENING MARKET 68
6 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE 69
6.1 INTRODUCTION 70
TABLE 6 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 70
6.2 REAGENTS & KITS 70
TABLE 7 KEY PRODUCTS IN THE REAGENTS & KITS MARKET 71
TABLE 8 BLOOD SCREENING REAGENTS & KITS MARKET, BY REGION, 2019–2026 (USD MILLION) 71
TABLE 9 BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 72
6.2.1 NAT REAGENTS & KITS 72
6.2.1.1 High sensitivity and rising use of NAT are boosting the demand for reagents & kits 72
6.2.1.2 Enzymes & polymerases 72
6.2.1.3 Standards & controls 72
6.2.1.4 Probes & primers 72
6.2.1.5 Buffers, nucleotides, and solutions 73
6.2.1.6 Labeling & detection reagents 73

6.3 PRIMARY NOTES 73
6.3.1 KEY INDUSTRY INSIGHTS 73
TABLE 10 KEY PRODUCTS IN THE NAT REAGENTS & KITS MARKET 73
TABLE 11 NAT REAGENTS & KITS MARKET, BY REGION, 2019–2026 (USD MILLION) 74
TABLE 12 NAT REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 74
6.3.2 ELISA REAGENTS & KITS 75
6.3.2.1 Ease of use and cost-effectiveness of ELISA reagents & kits will drive the market growth 75
6.3.2.2 Immunosorbents 75
6.3.2.3 Controls 75
6.3.2.4 Conjugates 75
6.3.2.5 Substrates 75
6.3.2.6 Sample diluents & wash solutions 75
TABLE 13 KEY PRODUCTS IN THE ELISA REAGENTS & KITS MARKET 76
TABLE 14 ELISA REAGENTS & KITS MARKET, BY REGION, 2019–2026 (USD MILLION) 76
TABLE 15 ELISA REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 77
6.3.3 OTHER REAGENTS & KITS 77
TABLE 16 KEY PRODUCTS IN THE OTHER REAGENTS & KITS MARKET 77
TABLE 17 OTHER BLOOD SCREENING REAGENTS & KITS MARKET, BY REGION, 2019–2026 (USD MILLION) 78
6.4 INSTRUMENTS 78
TABLE 18 KEY PRODUCTS IN THE BLOOD SCREENING INSTRUMENTS MARKET 79
TABLE 19 BLOOD SCREENING INSTRUMENTS MARKET, BY REGION, 2019–2026 (USD MILLION) 79
TABLE 20 BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 80
6.4.1 RENTAL PURCHASE 80
6.4.1.1 Convenience and cost-effectiveness of renting instruments has resulted in a greater end-user preference 80
TABLE 21 RENTAL PURCHASE MARKET FOR BLOOD SCREENING INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION) 81
6.4.2 OUTRIGHT PURCHASE 81
6.4.2.1 Availability of government support will increase the outright purchase of instruments 81
TABLE 22 OUTRIGHT PURCHASE MARKET FOR BLOOD SCREENING INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION) 81
6.5 SOFTWARE & SERVICES 82
6.5.1 GROWING PURCHASE OF INSTRUMENTS WILL DRIVE DEMAND FOR SOFTWARE & SERVICES 82
TABLE 23 KEY PRODUCTS IN THE SOFTWARE & SERVICES MARKET 82
TABLE 24 BLOOD SCREENING SOFTWARE & SERVICES, BY REGION, 2019–2026 (USD MILLION) 82
7 BLOOD SCREENING MARKET, BY TECHNOLOGY 83
7.1 INTRODUCTION 84
TABLE 25 BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 84
7.2 NUCLEIC ACID TEST 84
TABLE 26 KEY PRODUCTS IN THE NAT MARKET 85
TABLE 27 BLOOD SCREENING MARKET FOR NAT, BY REGION, 2019–2026 (USD MILLION) 86
TABLE 28 BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 86
7.2.1 TRANSCRIPTION-MEDIATED AMPLIFICATION 87
7.2.1.1 High sensitivity of these assays to support the market growth 87
TABLE 29 TMA MARKET, BY REGION, 2019–2026 (USD MILLION) 87
7.2.2 REAL-TIME POLYMERASE CHAIN REACTION 88
7.2.2.1 Real-time PCR provides more accurate and effective results as compared to conventional PCR 88
TABLE 30 RT-PCR MARKET, BY REGION, 2019–2026 (USD MILLION) 88
7.3 ENZYME-LINKED IMMUNOSORBENT ASSAY 89
TABLE 31 KEY PRODUCTS IN THE ELISA MARKET 90
TABLE 32 BLOOD SCREENING MARKET FOR ELISA, BY REGION, 2019–2026 (USD MILLION) 90
TABLE 33 BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 91
7.3.1 CHEMILUMINESCENT IMMUNOASSAYS 91
7.3.1.1 CLIA is ultra-sensitive, automated, and a good alternative to conventional technologies 91
TABLE 34 CLIA MARKET, BY REGION, 2019–2026 (USD MILLION) 91
7.3.2 FLUORESCENT IMMUNOASSAYS 92
7.3.2.1 Rising demand for safer and stable reagents and the development of novel markers to support the growth of the FIA market 92
TABLE 35 FIA MARKET, BY REGION, 2019–2026 (USD MILLION) 92
7.3.3 COLORIMETRIC IMMUNOASSAYS 93
7.3.3.1 CI offers low sensitivity as it uses vulnerable/limited signal amplification strategies 93
TABLE 36 CIA MARKET, BY REGION, 2019–2026 (USD MILLION) 93
7.4 RAPID TESTS 94
7.4.1 RISING AWARENESS ABOUT RAPID TESTS IN EMERGING COUNTRIES TO DRIVE MARKET GROWTH 94
TABLE 37 KEY PRODUCTS IN THE RAPID TESTS TECHNOLOGY MARKET 94
TABLE 38 BLOOD SCREENING MARKET FOR RAPID TESTS, BY REGION, 2019–2026 (USD MILLION) 95
7.5 WESTERN BLOT ASSAYS 95
7.5.1 GROWING PREVALENCE OF TTIS IN DEVELOPING COUNTRIES HAS RESULTED IN THE INCREASED DEMAND FOR WESTERN BLOT ASSAYS 95
TABLE 39 KEY PRODUCTS IN THE WESTERN BLOT ASSAYS MARKET 96
TABLE 40 BLOOD SCREENING MARKET FOR WESTERN BLOT ASSAYS, BY REGION, 2019–2026 (USD MILLION) 96

7.6 NEXT-GENERATION SEQUENCING 97
7.6.1 NGS IS AN EMERGING TECHNOLOGY IN THE BLOOD SCREENING MARKET 97
TABLE 41 BLOOD SCREENING MARKET FOR NGS, BY REGION, 2019–2026 (USD MILLION) 97
8 BLOOD SCREENING MARKET, BY END USER 98
8.1 INTRODUCTION 99
TABLE 42 BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 99
8.2 BLOOD BANKS 99
8.2.1 RISING DEMAND FOR BLOOD ATTRIBUTED TO INCREASING BLOOD DISORDER INCIDENCE 99
8.2.2 KEY INDUSTRY INSIGHTS 100
TABLE 43 BLOOD SCREENING MARKET FOR BLOOD BANKS, BY REGION,
2019–2026 (USD MILLION) 100
8.3 HOSPITALS 100
8.3.1 INCREASING SURGICAL PROCEDURES WILL DRIVE THE GROWTH OF THE HOSPITALS SEGMENT 100
TABLE 44 BLOOD SCREENING MARKET FOR HOSPITALS, BY REGION, 2019–2026 (USD MILLION) 101
9 BLOOD SCREENING MARKET, BY REGION 102
9.1 INTRODUCTION 103
TABLE 45 BLOOD SCREENING MARKET, BY REGION, 2019–2026 (USD MILLION) 103
9.2 NORTH AMERICA 103
FIGURE 28 NORTH AMERICA: BLOOD SCREENING MARKET SNAPSHOT 104
TABLE 46 NORTH AMERICA: BLOOD SCREENING MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 105
TABLE 47 NORTH AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 105
TABLE 48 NORTH AMERICA: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 105
TABLE 49 NORTH AMERICA: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 106
TABLE 50 NORTH AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 106
TABLE 51 NORTH AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 106
TABLE 52 NORTH AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 107
TABLE 53 NORTH AMERICA: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 107
9.2.1 US 107
9.2.1.1 The US dominated the North American blood screening market in 2020 107
TABLE 54 INCIDENCE OF VARIOUS CANCERS IN THE US, 2018 VS. 2025 108
TABLE 55 US: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 109
TABLE 56 US: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 109
TABLE 57 US: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 109
TABLE 58 US: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 110
TABLE 59 US: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 110
TABLE 60 US: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 110
TABLE 61 US: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 111
9.2.2 CANADA 111
9.2.2.1 Growing volume of surgical procedures performed and high burden of cancer to support market growth 111
TABLE 62 CANADA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 112
TABLE 63 CANADA: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 112
TABLE 64 CANADA: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 112
TABLE 65 CANADA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 113
TABLE 66 CANADA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 113
TABLE 67 CANADA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 113
TABLE 68 CANADA: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 114
9.3 EUROPE 114
TABLE 69 EUROPE: BLOOD SCREENING MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 114
TABLE 70 EUROPE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 115
TABLE 71 EUROPE: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 115
TABLE 72 EUROPE: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 115
TABLE 73 EUROPE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 116
TABLE 74 EUROPE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 116
TABLE 75 EUROPE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 116
TABLE 76 EUROPE: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 117

9.3.1 GERMANY 117
9.3.1.1 Higher healthcare spending and increase in cancer prevalence drives market growth 117
TABLE 77 GERMANY: KEY MACROINDICATORS 117
TABLE 78 GERMANY: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 118
TABLE 79 GERMANY: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 118
TABLE 80 GERMANY: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 118
TABLE 81 GERMANY: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 119
TABLE 82 GERMANY: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 119
TABLE 83 GERMANY: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 119
TABLE 84 GERMANY: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 120
9.3.2 FRANCE 120
9.3.2.1 Increasing prevalence of HIV to support the market growth 120
TABLE 85 FRANCE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 120
TABLE 86 FRANCE: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 121
TABLE 87 FRANCE: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 121
TABLE 88 FRANCE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 121
TABLE 89 FRANCE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 122
TABLE 90 FRANCE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 122
TABLE 91 FRANCE: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 122
9.3.3 UK 123
9.3.3.1 Government support to prevent transmission of HIV and other infections will drive market growth 123
TABLE 92 UK: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 123
TABLE 93 UK: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 124
TABLE 94 UK: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 124
TABLE 95 UK: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 124
TABLE 96 UK: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 125
TABLE 97 UK: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 125
TABLE 98 UK: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 125
9.3.4 ITALY 126
9.3.4.1 Italy is witnessing an increase in the number of blood donors 126
TABLE 99 ITALY: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 126
TABLE 100 ITALY: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 126
TABLE 101 ITALY: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 127
TABLE 102 ITALY: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 127
TABLE 103 ITALY: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 127
TABLE 104 ITALY: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 128
TABLE 105 ITALY: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 128
9.3.5 SPAIN 128
9.3.5.1 Increasing adoption of NAT technology will support market growth 128
TABLE 106 SPAIN: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 129
TABLE 107 SPAIN: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 129
TABLE 108 SPAIN: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 129
TABLE 109 SPAIN: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 130
TABLE 110 SPAIN: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 130
TABLE 111 SPAIN: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 130
TABLE 112 SPAIN: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 131
9.3.6 REST OF EUROPE 131
TABLE 113 ROE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2018 (% OF GDP) 131
TABLE 114 ROE: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 132
TABLE 115 ROE: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 132
TABLE 116 ROE: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 132
TABLE 117 ROE: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 133
TABLE 118 ROE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 133
TABLE 119 ROE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 133
TABLE 120 ROE: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 134
9.4 ASIA PACIFIC 134
FIGURE 29 ASIA PACIFIC: BLOOD SCREENING MARKET SNAPSHOT 135
TABLE 121 ASIA PACIFIC: BLOOD SCREENING MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 136
TABLE 122 ASIA PACIFIC: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 136
TABLE 123 ASIA PACIFIC: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 136
TABLE 124 ASIA PACIFIC: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 137
TABLE 125 ASIA PACIFIC: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 137
TABLE 126 ASIA PACIFIC: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 137
TABLE 127 ASIA PACIFIC: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 138
TABLE 128 ASIA PACIFIC: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 138
9.4.1 CHINA 138
9.4.1.1 China has a high prevalence of infectious diseases 138
TABLE 129 CHINA: KEY MACROINDICATORS 139
TABLE 130 CHINA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 139
TABLE 131 CHINA: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 140
TABLE 132 CHINA: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 140
TABLE 133 CHINA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 140
TABLE 134 CHINA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 141
TABLE 135 CHINA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 141
TABLE 136 CHINA: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 141
9.4.2 JAPAN 142
9.4.2.1 Rising geriatric population and prevalence of cancer support market growth 142
TABLE 137 JAPAN: KEY MACROINDICATORS 142
TABLE 138 JAPAN: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 143
TABLE 139 JAPAN: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 143
TABLE 140 JAPAN: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 143
TABLE 141 JAPAN: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 144
TABLE 142 JAPAN: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 144
TABLE 143 JAPAN: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 144
TABLE 144 JAPAN: BLOOD SCREENING MARKET, BY END USER,
2019–2026 (USD MILLION) 145
9.4.3 INDIA 145
9.4.3.1 Increasing number of road accidents and rise in prevalence of thalassemia will support the market growth 145
TABLE 145 INDIA: KEY MACROINDICATORS 146
TABLE 146 INDIA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 146
TABLE 147 INDIA: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 146
TABLE 148 INDIA: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM,
2019–2026 (USD MILLION) 147
TABLE 149 INDIA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 147
TABLE 150 INDIA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE,
2019–2026 (USD MILLION) 147
TABLE 151 INDIA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 148
TABLE 152 INDIA: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 148
9.4.4 AUSTRALIA 148
9.4.4.1 Increased demand for blood donations will propel market growth 148
TABLE 153 AUSTRALIA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 149
TABLE 154 AUSTRALIA: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 149
TABLE 155 AUSTRALIA: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 149
TABLE 156 AUSTRALIA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 150
TABLE 157 AUSTRALIA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 150
TABLE 158 AUSTRALIA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 150
TABLE 159 AUSTRALIA: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 151
9.4.5 REST OF ASIA PACIFIC 151
TABLE 160 ROAPAC: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 152
TABLE 161 ROAPAC: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 152
TABLE 162 ROAPAC: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 152
TABLE 163 ROAPAC: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 153
TABLE 164 ROAPAC: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 153
TABLE 165 ROAPAC: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 153
TABLE 166 ROAPAC: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 154
9.5 LATIN AMERICA 154
TABLE 167 LATIN AMERICA: BLOOD SCREENING MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 155
TABLE 168 LATIN AMERICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 155
TABLE 169 LATIN AMERICA: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 155
TABLE 170 LATIN AMERICA: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 156
TABLE 171 LATIN AMERICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 156
TABLE 172 LATIN AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 156
TABLE 173 LATIN AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 157
TABLE 174 LATIN AMERICA: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 157
9.5.1 BRAZIL 157
9.5.1.1 Increased prevalence of cancer will support the market growth 157
TABLE 175 INCIDENCE OF VARIOUS CANCERS IN BRAZIL, 2020 VS. 2025 157
TABLE 176 BRAZIL: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 158
TABLE 177 BRAZIL: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 158
TABLE 178 BRAZIL: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 158
TABLE 179 BRAZIL: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 159
TABLE 180 BRAZIL: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 159
TABLE 181 BRAZIL: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 159
TABLE 182 BRAZIL: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 160
9.5.2 REST OF LATIN AMERICA 160
TABLE 183 ROLATAM: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 160
TABLE 184 ROLATAM: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 161
TABLE 185 ROLATAM: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 161
TABLE 186 ROLATAM: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 161
TABLE 187 ROLATAM: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 162
TABLE 188 ROLATAM: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 162
TABLE 189 ROLATAM: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 162
9.6 MIDDLE EAST & AFRICA 163
9.6.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 163
TABLE 190 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 164
TABLE 191 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION) 164
TABLE 192 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION) 164
TABLE 193 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 165
TABLE 194 MIDDLE EAST & AFRICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION) 165
TABLE 195 MIDDLE EAST & AFRICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION) 165
TABLE 196 MIDDLE EAST & AFRICA: BLOOD SCREENING MARKET, BY END USER, 2019–2026 (USD MILLION) 166
10 COMPETITIVE LANDSCAPE 167
10.1 OVERVIEW 167
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 167
10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE BLOOD SCREENING MARKET 168
TABLE 197 OVERVIEW OF STRATEGIES DEPLOYED BY KEY BLOOD SCREENING MANUFACTURING COMPANIES 168
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 169
FIGURE 30 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE BLOOD SCREENING MARKET 169
10.4 MARKET SHARE ANALYSIS 170
FIGURE 31 BLOOD SCREENING MARKET SHARE, BY KEY PLAYER (2020) 170
TABLE 198 BLOOD SCREENING MARKET: DEGREE OF COMPETITION 170
10.5 COMPANY EVALUATION QUADRANT 171
10.5.1 LIST OF EVALUATED VENDORS 171
10.5.2 STARS 171
10.5.3 EMERGING LEADERS 172
10.5.4 PERVASIVE PLAYERS 172
10.5.5 PARTICIPANTS 172
FIGURE 32 BLOOD SCREENING MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020 172

10.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020) 173
10.6.1 PROGRESSIVE COMPANIES 173
10.6.2 STARTING BLOCKS 173
10.6.3 RESPONSIVE COMPANIES 173
10.6.4 DYNAMIC COMPANIES 173
FIGURE 33 BLOOD SCREENING MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020 174
10.7 COMPETITIVE BENCHMARKING 175
10.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS 175
FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE BLOOD SCREENING MARKET 175
TABLE 199 PRODUCT FOOTPRINT OF COMPANIES 175
TABLE 200 REGIONAL FOOTPRINT OF COMPANIES 175
10.8 COMPETITIVE SCENARIO 176
10.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS 176
TABLE 201 KEY PRODUCT LAUNCHES 176
10.8.2 DEALS 176
TABLE 202 KEY DEALS 176
11 COMPANY PROFILES 177
(Business Overview, Products, Key Insights, Recent Developments, MnM View)*
11.1 KEY PLAYERS 177
11.1.1 F. HOFFMANN-LA ROCHE 177
TABLE 203 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW 177
FIGURE 35 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2020) 178
11.1.2 GRIFOLS 182
TABLE 204 GRIFOLS: BUSINESS OVERVIEW 182
FIGURE 36 GRIFOLS: COMPANY SNAPSHOT (2020) 183
11.1.3 ABBOTT LABORATORIES 187
TABLE 205 ABBOTT LABORATORIES: BUSINESS OVERVIEW 187
FIGURE 37 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 188
11.1.4 BIOMÉRIEUX 191
TABLE 206 BIOMÉRIEUX: BUSINESS OVERVIEW 191
FIGURE 38 BIOMÉRIEUX: COMPANY SNAPSHOT (2020) 192
11.1.5 BIO-RAD LABORATORIES 194
TABLE 207 BIO-RAD LABORATORIES: BUSINESS OVERVIEW 194
FIGURE 39 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020) 195
11.1.6 BECTON, DICKINSON AND COMPANY 199
TABLE 208 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 199
FIGURE 40 BD: COMPANY SNAPSHOT (2020) 200

11.1.7 DANAHER CORPORATION 202
TABLE 209 DANAHER CORPORATION.: BUSINESS OVERVIEW 202
FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 203
11.1.8 DIASORIN 205
TABLE 210 DIASORIN: BUSINESS OVERVIEW 205
FIGURE 42 DIASORIN: COMPANY SNAPSHOT (2020) 206
11.1.9 SIEMENS HEALTHINEERS 209
TABLE 211 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW 209
FIGURE 43 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020) 210
11.1.10 THERMO FISHER SCIENTIFIC, INC. 212
TABLE 212 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 212
FIGURE 44 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020) 213
(Business Overview, Products, Key Insights, Recent Developments, MnM View)*
11.2 OTHER PLAYERS 215
11.2.1 ORTHO CLINICAL DIAGNOSTICS, INC. 215
11.2.2 GE HEALTHCARE 216
11.2.3 MERCK KGAA 217
11.2.4 PERKINELMER 218
11.2.5 BIO-TECHNE CORPORATION 219
11.2.6 GFE 220
11.2.7 TRINITY BIOTECH 221
11.2.8 J. MITRA & CO. PVT. LTD. 222
11.2.9 MINDRAY 223
11.2.10 MACCURA BIOTECHNOLOGY CO., LTD. 224
11.2.11 IMMUCOR, INC. 225
11.2.12 CELLABS 225
11.2.13 ABNOVA CORPORATION 226
11.2.14 ENZO BIOCHEM, INC. 226
11.2.15 CEPHEID 227
12 APPENDIX 228
12.1 DISCUSSION GUIDE 228
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 232
12.3 AVAILABLE CUSTOMIZATIONS 234
12.4 RELATED REPORTS 234
12.5 AUTHOR DETAILS 235

ページTOPに戻る

Table of Contents

Summary

The global blood screening market is projected to reach USD 3.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 8.4% during the forecast period. Growth in this market is mainly driven by the growing number of blood donations across the world, the rising prevalence of infectious diseases, and the rising demand for donated blood.

"The reagents & kits segment accounted for the highest growth rate in the blood screening market, by product & service, during the forecast period."
The blood screening market is segmented into reagents & kits, instruments, and software & services based on product. In 2020, the reagents & kits segment accounted for the highest growth rate in the blood screening market. Market growth can largely be attributed to rising number of blood transfusions and blood donations. In addition, technological advancements in blood screening technologies and the increasing number of surgeries are stimulating the growth of this segment.
"Blood banks segment accounted for the highest CAGR."
Based on end users, the blood screening market is segmented into blood banks and hospitals. In 2020, the blood banks segment accounted for the highest growth rate. This can be attributed to the growing number of organ transplantation surgeries, and rising awareness about blood safety.
"Asia Pacific: The fastest-growing region blood screening market."
The global blood screening market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Factors such as the increasing healthcare spending, increasing government efforts to increase awareness about early disease detection, growing per capita income, expansion of private-sector hospitals to rural areas in various APAC countries, the rising geriatric population in several APAC countries (coupled with the increasing prevalence of chronic disorders), and the presence of high-growth markets in the region. The low labor costs and the favorable regulatory environment in this region are also expected to propel market growth.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6% , and the Middle East & Africa – 4%
Lists of Companies Profiled in the Report:

• Grifols (Spain)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Abbott Laboratories, Inc. (US), bioMérieux (France)
• Bio-Rad Laboratories, Inc. (US)
• Becton, Dickinson and Company (US)
• Beckman Coulter, Inc. (Danaher) (US)
• DiaSorin (Italy)
• Siemens Healthineers (Germany)
• Thermo Fisher Scientific, Inc. (US)
• Ortho Clinical Diagnostics Inc. (US)
• GE Healthcare (US)
• Merck KGaA (Germany)
• PerkinElmer (US)
• Bio-Techne Corporation (US)
• GFE (Germany)
• Trinity Biotech (Ireland)
• Mindray (China)
• Maccura Biotechnology Co., Ltd. (China)
• Immucor, Inc. (US)
• Cellabs (Australia)
• Abnova Corporation (Taiwan)
• Enzo Biochem, Inc. (US)
• Cepheid (US).
Research Coverage:
This report provides a detailed picture of the global blood screening market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall blood screening market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（金融）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（acid）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（金融）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（acid）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?